Gastrin peptide immunogenic composition

Inventors

Mudde, Geert Cornelius • Broome, Paul Christopher • Jacobs, Frederick William • Langer, Christof

Assignees

TYG ONCOLOGY Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10328134-B2

Patent

Publication Date

2019-06-25

Expiration Date


Abstract

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases.

Core Innovation

The invention provides an immunogenic composition that combines a directed adjuvant and a gastrin-17 peptide immunogen for inducing an immune response against gastrin-17. The directed adjuvant comprises at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix. The anti-CD32 moiety specifically binds CD32 and is selected from antibodies, antibody fragments, proteins, or peptides.

The composition further comprises a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix. The gastrin-17 peptide immunogen comprises an amino acid sequence of SEQ ID NOS: 1, 6, 8, or 9, or the peptide immunogen of SEQ ID NO:10. The first and second peptidic alpha-helices are repeats of matching coil repeat sequences selected from the group consisting of SEQ ID NOs: 14, 16, 18, 21, 24, 27, 30, and 33.

In the described system, the directed adjuvant and the gastrin-17 immunogen are arranged using alpha-helix coiled-coil pairing. Helix-coil repeat motifs are stated to provide high-affinity coiled-coil pairing with stated Kd thresholds. The TLR9 ligand is a TLR9 agonist selected from CpG oligodeoxynucleotide class A, B, and C, with the intent to drive Th1-promoting immune polarization.

Claims Coverage

The independent claim covers an immunogenic composition with two main inventive parts: a directed adjuvant that targets CD32 and includes a TLR9 agonist and a first peptidic alpha-helix, and a gastrin-17 peptide immunogen linked to a second matching peptidic alpha-helix coiled to the first helix. The claim further constrains the immunogen to specific SEQ ID-defined gastrin-17 peptide options and constrains the helix pairing to specified coil repeat sequences.

Directed adjuvant with anti-CD32 linked to a TLR9 agonist and a first alpha-helix

A directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, wherein the anti-CD32 moiety specifically binds CD32 and is selected from antibodies, antibody fragments, proteins, or peptides, and the TLR9 ligand is a TLR9 agonist selected from CpG oligodeoxynucleotide class A, B, and C.

Gastrin-17 peptide immunogen linked to a second matching alpha-helix coiled to the first

A gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, wherein the peptide immunogen comprises the amino acid sequence of SEQ ID NOS: 1, 6, 8, or 9; or the peptide immunogen of SEQ ID NO:10.

Matching coil repeat sequences for helix coiled pairing

The first and second peptidic alpha-helices are repeats of matching coil repeat sequences selected from the group consisting of SEQ ID NOs: 14, 16, 18, 21, 24, 27, 30, and 33.

Overall, the independent claim centers on coupling a CD32-targeting directed adjuvant to a gastrin-17 peptide immunogen linked by coiled-coil alpha-helix pairing. Claim coverage is grounded in specific SEQ ID-defined gastrin-17 peptide sequences and specified coil repeat sequences that govern matching alpha-helix repeats.

Stated Advantages

Induces an immunogenic response against gastrin-17 using a directed adjuvant combined with a coiled-coil linked gastrin-17 peptide immunogen.

Stated to provide high-affinity coiled-coil pairing with stated Kd thresholds.

TLR9 agonist use is stated to drive Th1-promoting immune polarization.

Reported induction of IgG against G17 components and reported cross-reactivity to human G17 in experimental examples.

Reported weight/appetite effects suggesting obesity control.

Reported indications for gastrin-dependent cancers, including pancreatic cancer.

Documented Applications

Cancer and other gastrin-dependent conditions listed in the provided claim-derived context: pancreatic cancer, gastric ulcer, GERD, end-stage renal failure (ESRF), and obesity.

Experimental use in animals including mice and cynomolgus monkeys, with reported IgG induction against G17 components and cross-reactivity to human G17.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.